fashion -WSS

fashion

author：knowledge 2025-10-01 14:20:03 - browse：248

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.

The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Argenx readies a blockbuster opportunity with drug for autoimmune disease

entertainment

WSS

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Orchard's therapy for neuron disease in children wins FDA approval

Gene editing the human germline: What are the risks?

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Virtual Event: March of the Biosimilars

focus

fashion

focus

Malaria cases in Florida and Texas: Here’s what you need to know

FDA clears Verve to begin U.S. study of gene

The cancer drug shortage isn’t new — and neither are the solutions

AstraZeneca to buy developer of next

Trump demands the U.S. pay no more for drugs than other countries … again

How AI can help patients find reliable information about doctors

Psychedelics group wrestles with new pharma identity

The problems with dementia villages

Heart attack and stroke risk calculators need revising

Orchard's therapy for neuron disease in children wins FDA approval

leisure time

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

ADCs take center stage as promising cancer treatments

Orchard's therapy for neuron disease in children wins FDA approval

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

focus

entertainment

Wikipedia

focus